These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15310787)

  • 1. Serum selenium in lymphoma.
    Beguin Y; Weber G
    J Clin Oncol; 2004 Aug; 22(16):3429; author reply 3430. PubMed ID: 15310787
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune deficiency in malignant lymphomas.
    Konopka L; Pawelski S; Maślanka K; Zupańska B; Cieśluk S
    Chemioterapia; 1987 Jun; 6(2 Suppl):745-8. PubMed ID: 3509538
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of malignant lymphoma].
    Shimoyama M
    Gan No Rinsho; 1989 Jan; Spec No():593-604. PubMed ID: 2783748
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary Hepatic Lymphoma.
    Martin P; Daniel SP; Conlon S; Walshe J; Grogan L
    Ir Med J; 2005 Sep; 98(8):244-6. PubMed ID: 16255120
    [No Abstract]   [Full Text] [Related]  

  • 5. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
    Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphomas.
    Santoro A; Castagna L; Magagnoli M
    Cancer Chemother Biol Response Modif; 2003; 21():399-428. PubMed ID: 15338757
    [No Abstract]   [Full Text] [Related]  

  • 7. Avascular necrosis following combination chemotherapy.
    Gopal R; Saikia TK; Nair CN; Nadkarni KS; Dinshaw KA; Pande SC; Mehta AR; Advani SH; Talwalkar GA
    Indian J Cancer; 1985 Sep; 22(3):221-7. PubMed ID: 3843324
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effectiveness of platidiam in the chemotherapy of lymphogranulomatosis and lymphosarcoma].
    Korol'chuk LV; Kruglova GV
    Ter Arkh; 1987; 59(6):37-40. PubMed ID: 3307012
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
    Attarbaschi A; Dworzak M; Steiner M; Urban C; Fink FM; Reiter A; Gadner H; Mann G
    Pediatr Blood Cancer; 2005 Jan; 44(1):70-6. PubMed ID: 15368550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dicarbamine as a hemoprotective agent in patients with hemoblastoses treated with chemotherapy].
    Ivanova OV
    Vopr Onkol; 2012; 58(3):416-9. PubMed ID: 22888661
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum VEGF as a significant marker of treatment response in hodgkin lymphoma.
    Ben Arush MW; Ben Barak A; Maurice S; Livne E
    Pediatr Hematol Oncol; 2007 Mar; 24(2):111-5. PubMed ID: 17454776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the treatment of lymphoma.
    Portlock CS
    Curr Opin Oncol; 1990 Oct; 2(5):838-42. PubMed ID: 2095888
    [No Abstract]   [Full Text] [Related]  

  • 13. [Quantitative-kinetic aspects of granulocytic resistance to infection in hematologic systemic diseases with reference to antineoplastic chemotherapy].
    Sommer S
    Z Arztl Fortbild (Jena); 1988; 82(11):513-5. PubMed ID: 3176536
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of cytostatic therapy in hemoblastoses on phagocytosis of neutrophilic granulocytes].
    Gottschalk U; Stobbe H
    Z Arztl Fortbild (Jena); 1986; 80(23):981-3. PubMed ID: 3472417
    [No Abstract]   [Full Text] [Related]  

  • 15. [Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?].
    Bence Z; Kovács G; Jakab Z; Csóka M; Müller J
    Magy Onkol; 2008 Dec; 52(4):357-62. PubMed ID: 19068463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin's lymphoma.
    Soubeyran P; Masmoudi A; Blanc-Bisson C; Quénel N; Hoerni B; Bellott R; Robert J; Soubeyran I; Donamaria C; Molimard M
    Eur J Cancer; 2007 Jan; 43(1):53-4. PubMed ID: 16824747
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-associated lymphoma.
    Kaplan LD
    AIDS Clin Rev; 1993-1994; ():145-66. PubMed ID: 8217897
    [No Abstract]   [Full Text] [Related]  

  • 18. [Progress in therapeutic strategy for malignant lymphoma].
    Ogura M
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):309-27. PubMed ID: 15791814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor markers in malignant lymphoma].
    Kato H; Ogura M
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
    Korolenko VO; Gershanovich ML; Tikhonova VV
    Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.